Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Illustration of DNA

The study, published today in Molecular Cell, shows how everyday DNA damage, which occurs naturally in all cells, can become a serious problem when ATM is missing. The findings help explain how some cancers respond to treatment and may also provide new insights into a rare genetic condition called ataxia-telangiectasia (A-T).

Professor Ross Chapman from the MRC Weatherall Institute of Molecular Medicine said: "Our DNA is constantly damaged by normal processes inside the body. Most of this damage is quickly repaired and causes no lasting harm. However, we found that ATM plays an important role in helping cells safely copy DNA when that damage is present."

Solving a 20-year-old cancer research puzzle

Scientists have long known that PARP inhibitors are effective against cancers with faults in certain DNA repair pathways, including some cancers caused by inherited mutations in the BRCA1 and BRCA2 genes (most commonly breast and ovarian cancers). However, researchers have also observed that cancers lacking ATM can respond to these drugs, even though they do not have the same repair defects as BRCA-related cancers. Until now, the reason has remained unclear.

The new study, led by Lucia Sommerova, Ashleigh King and Professor Ross Chapman in the MRC Molecular Haematology Unit, reveals that ATM helps cells cope with common forms of DNA damage while they are copying their genetic material before cell division.

"When ATM is missing, cells struggle to deal with this damage properly," added Professor Chapman. "Instead, they leave behind small gaps in newly copied DNA. These gaps trigger repair processes involving PARP proteins and make the cells increasingly dependent on those repair pathways to survive."

This creates an unexpected weakness. When PARP is blocked by drugs such as olaparib, ATM-deficient cells can no longer cope with the accumulating damage and are more likely to die.

How everyday DNA damage creates a hidden weakness

Importantly, the researchers found that the problem is not caused by rare or extreme forms of DNA damage. Instead, it arises from oxidative DNA damage, a common type of wear and tear caused by normal cellular activity.

The team identified a DNA-copying protein called PRIMPOL as a key part of this process. When they prevented PRIMPOL from restarting DNA copying beyond damaged sites, ATM-deficient cells became much less sensitive to olaparib. Reducing oxidative stress also reduced many of the DNA-copying problems seen in cells lacking ATM, strengthening the link between everyday DNA damage and the vulnerability uncovered by the researchers.

What the findings could mean for cancer treatment

ATM is altered in many types of cancer, including prostate, pancreatic, stomach and lung cancers. The findings provide a new explanation for why some ATM-deficient cancers may respond to PARP inhibitors and suggest that these cancers are vulnerable for different reasons than cancers with BRCA mutations. Understanding those differences could help researchers learn why patients respond differently to treatment and improve the use of these drugs in the future.

New clues about a rare genetic condition

The study may also help researchers understand ataxia-telangiectasia, a rare inherited condition caused by the loss of ATM. Oxidative stress has long been linked to the disease, but exactly why it is so harmful has been difficult to explain. The new findings suggest that everyday oxidative DNA damage may become particularly harmful when cells lacking ATM try to copy their DNA.

Read the full paper here: ATM safeguards DNA replication by restraining pathological repriming at endogenous base lesions

Similar stories

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.

Similar stories

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.